Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
about
Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decadeFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsChildren's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersAntitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesIdentification of single- and multiple-class specific signature genes from gene expression profiles by group marker indexCell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcomaUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsIs fibroblast growth factor receptor 4 a suitable target of cancer therapy?The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.Pediatric Rhabdomyosarcoma.Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyArtificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancerGenome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.Animal models of soft-tissue sarcoma.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancerInitial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.The Fibroblast Growth Factor signaling pathwayA recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Pitfalls in experimental designs for characterizing the transcriptional, methylational and copy number changes of oncogenes and tumor suppressor genes.FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancerDFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Clonality and evolutionary history of rhabdomyosarcomaChallenging issues in pediatric oncologyThe prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Childhood rhabdomyosarcoma: recent advances and prospective views.Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells.Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response
P2860
Q26770333-6C19EB4F-11B2-440B-A9A8-535364B74A34Q26801718-B56DFF28-13BD-4BF7-B26A-D75B7B08198FQ26825000-06C3EAD3-6E20-4B73-8CDF-850CEDF2FCC5Q26998790-0772CCB0-4DB1-49E4-9D5B-BFAA43210890Q26998955-3A59D0FB-9665-4DCB-9A4D-B4C79B876AB5Q27853244-232EE009-DCC4-4229-AE06-1A8309946904Q28079232-57182C8C-E406-406F-A2CE-70A778AC5F26Q28476766-BB5188B5-0D96-4676-89B7-1ACB36C6FDD3Q28485302-C893CA58-C63D-4459-842B-AF7FF9C85A1FQ28546245-3E68CCC6-EEBC-41B5-AF10-9A3CC008CE45Q33751398-0281B6A9-061B-453A-9F14-8CE5498F886DQ33784827-56E2B3B9-0223-4AD0-8AE1-486FC3ECF2A1Q33842070-3C5469E8-3AF7-424A-B9C3-2C6E0FE6A1C6Q33885479-BB4A6CEA-401E-4A8A-9740-F4DF8FE801EDQ33904902-E68D2810-B5D4-422C-BD54-8C2CFB483878Q33993529-1C2237FF-1910-4D73-AA88-0EAAD0C50E2BQ34069048-4F5A7D33-1F09-46EE-9893-31D2A4BE66A6Q34098113-431D6BF0-2EEB-46B5-B9E7-D58279B4E69AQ34273411-BAD67038-25F9-4CFA-BEB5-A7297375BD20Q34358404-0B6C67A9-4DEE-41A6-B410-711513545869Q34361391-B62BFA0A-BFEA-4456-8D7F-761EF883A24DQ34467171-7A152984-D07F-4E5F-B1C1-92CF98871274Q34507108-F11ABF0F-0D8F-43F7-AD72-5D2B30D46BA2Q34525925-30DA0706-EF9E-4F77-B1EF-36FF7933E58BQ34614747-4581D007-202E-4D4D-B677-AD61E9A5C3CAQ34733972-3BE7D2EB-6A90-4188-90E4-B299F755BE2DQ34992813-4EBC9FAF-2DE2-4F3F-B10B-C4257744A973Q35017004-A7C8502F-BD91-4EF0-BAA9-7573FEC96BA2Q35096201-BEB0802A-D9D1-4A77-B8FB-E469F5899B8AQ35175269-9203E00A-0B84-4E2A-8CBE-192584586681Q35602419-1D3C02FF-D42F-47DD-B011-A911B6D5B529Q35659865-27F7FF57-736E-4B7C-8169-7746601B5041Q35667137-89C29D72-39FB-447B-B7FE-A3A2F24ED163Q35711420-F1AB3F93-A535-4DCC-9909-FEF209A7F7AAQ35729391-EC76D19A-DD54-4A38-8D0B-C26314A328C5Q35752926-6FEDE178-A78E-400D-880F-F1FBCEC100E7Q35847829-0B2138B1-A716-4383-B0C7-2DA23823400FQ35863493-2EEEA96C-2984-4B63-BC52-32E368FE52ABQ35882212-8FB18E80-21F8-4FA2-8210-37BFE58B5207Q35929495-27031420-56AF-4FF5-95E1-C0874F61712A
P2860
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Identification of FGFR4-activa ...... is in xenotransplanted models.
@ast
Identification of FGFR4-activa ...... is in xenotransplanted models.
@en
type
label
Identification of FGFR4-activa ...... is in xenotransplanted models.
@ast
Identification of FGFR4-activa ...... is in xenotransplanted models.
@en
prefLabel
Identification of FGFR4-activa ...... is in xenotransplanted models.
@ast
Identification of FGFR4-activa ...... is in xenotransplanted models.
@en
P2093
P2860
P50
P356
P1476
Identification of FGFR4-activa ...... is in xenotransplanted models.
@en
P2093
Adam T Cheuk
Arnulfo Mendoza
Chand Khanna
Choh Yeung
Daniel Catchpoole
Glenn Merlino
Javed Khan
Krupa Desai
P2860
P304
P356
10.1172/JCI39703
P407
P577
2009-10-05T00:00:00Z